Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

The CD38low natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide.

Sarkar S, Chauhan SKS, Daly J, Natoni A, Fairfield H, Henderson R, Nolan E, Swan D, Hu J, Reagan MR, O'Dwyer M.

Cancer Immunol Immunother. 2020 Jan 9. doi: 10.1007/s00262-019-02477-8. [Epub ahead of print]

PMID:
31919623
2.

In Vitro 3D Cultures to Reproduce the Bone Marrow Niche.

Ham J, Lever L, Fox M, Reagan MR.

JBMR Plus. 2019 Oct 1;3(10):e10228. doi: 10.1002/jbm4.10228. eCollection 2019 Oct. Review.

3.

Therapeutic Irradiation: Consequences for Bone and Bone Marrow Adipose Tissue.

Costa S, Reagan MR.

Front Endocrinol (Lausanne). 2019 Aug 29;10:587. doi: 10.3389/fendo.2019.00587. eCollection 2019. Review.

4.

Development of medical-grade, discrete, multi-walled carbon nanotubes as drug delivery molecules to enhance the treatment of hematological malignancies.

Falank C, Tasset AW, Farrell M, Harris S, Everill P, Marinkovic M, Reagan MR.

Nanomedicine. 2019 Aug;20:102025. doi: 10.1016/j.nano.2019.102025. Epub 2019 Jun 4.

PMID:
31170511
5.

Sialyltransferase inhibition leads to inhibition of tumor cell interactions with E-selectin, VCAM1, and MADCAM1, and improves survival in a human multiple myeloma mouse model.

Natoni A, Farrell ML, Harris S, Falank C, Kirkham-McCarthy L, Macauley MS, Reagan MR, O'Dwyer M.

Haematologica. 2020 Jan 31;105(2):457-467. doi: 10.3324/haematol.2018.212266. Print 2020.

6.

Inverse correlation between trabecular bone volume and bone marrow adipose tissue in rats treated with osteoanabolic agents.

Costa S, Fairfield H, Reagan MR.

Bone. 2019 Jun;123:211-223. doi: 10.1016/j.bone.2019.03.038. Epub 2019 Apr 4.

PMID:
30954729
7.

Multiple Myeloma and Fatty Acid Metabolism.

Masarwi M, DeSchiffart A, Ham J, Reagan MR.

JBMR Plus. 2019 Feb 20;3(3):e10173. doi: 10.1002/jbm4.10173. eCollection 2019 Mar. Review.

8.

2D and 3D In Vitro Co-Culture for Cancer and Bone Cell Interaction Studies.

Marino S, Bishop RT, de Ridder D, Delgado-Calle J, Reagan MR.

Methods Mol Biol. 2019;1914:71-98. doi: 10.1007/978-1-4939-8997-3_5.

PMID:
30729461
9.

Interleukin-6 Interweaves the Bone Marrow Microenvironment, Bone Loss, and Multiple Myeloma.

Harmer D, Falank C, Reagan MR.

Front Endocrinol (Lausanne). 2019 Jan 8;9:788. doi: 10.3389/fendo.2018.00788. eCollection 2018. Review.

10.

Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche.

Tsukamoto S, Løvendorf MB, Park J, Salem KZ, Reagan MR, Manier S, Zavidij O, Rahmat M, Huynh D, Takagi S, Kawano Y, Kokubun K, Thrue CA, Nagano K, Petri A, Roccaro AM, Capelletti M, Baron R, Kauppinen S, Ghobrial IM.

Leukemia. 2018 Aug;32(8):1739-1750. doi: 10.1038/s41375-018-0161-6. Epub 2018 Jun 20.

PMID:
29925904
11.

Soluble and Cell-Cell-Mediated Drivers of Proteasome Inhibitor Resistance in Multiple Myeloma.

Farrell ML, Reagan MR.

Front Endocrinol (Lausanne). 2018 May 1;9:218. doi: 10.3389/fendo.2018.00218. eCollection 2018. Review.

12.

3d Tissue Engineered In Vitro Models Of Cancer In Bone.

Sitarski AM, Fairfield H, Falank C, Reagan MR.

ACS Biomater Sci Eng. 2018 Feb 12;4(2):324-336. doi: 10.1021/acsbiomaterials.7b00097. Epub 2017 Jun 9.

13.

Reflections on Cancer in the Bone Marrow: Adverse Roles of Adipocytes.

Falank C, Fairfield H, Reagan MR.

Curr Mol Biol Rep. 2017 Dec;3(4):254-262. doi: 10.1007/s40610-017-0074-6. Epub 2017 Oct 19.

14.

Development of a 3D bone marrow adipose tissue model.

Fairfield H, Falank C, Farrell M, Vary C, Boucher JM, Driscoll H, Liaw L, Rosen CJ, Reagan MR.

Bone. 2019 Jan;118:77-88. doi: 10.1016/j.bone.2018.01.023. Epub 2018 Jan 31.

15.

Metformin Affects Cortical Bone Mass and Marrow Adiposity in Diet-Induced Obesity in Male Mice.

Bornstein S, Moschetta M, Kawano Y, Sacco A, Huynh D, Brooks D, Manier S, Fairfield H, Falank C, Roccaro AM, Nagano K, Baron R, Bouxein M, Vary C, Ghobrial IM, Rosen CJ, Reagan MR.

Endocrinology. 2017 Oct 1;158(10):3369-3385. doi: 10.1210/en.2017-00299.

16.

Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing.

Moschetta M, Kawano Y, Sacco A, Belotti A, Ribolla R, Chiarini M, Giustini V, Bertoli D, Sottini A, Valotti M, Ghidini C, Serana F, Malagola M, Imberti L, Russo D, Montanelli A, Rossi G, Reagan MR, Maiso P, Paiva B, Ghobrial IM, Roccaro AM.

Curr Osteoporos Rep. 2017 Oct;15(5):499-506. doi: 10.1007/s11914-017-0399-3. Review.

PMID:
28889371
17.

Cover Image, Volume 232, Number 12, December 2017.

Reagan MR, Lian JB, Rosen CJ, Stein GS.

J Cell Physiol. 2017 Dec;232(12):i. doi: 10.1002/jcp.25563.

PMID:
28833120
18.

Connecting Bone and Fat: The Potential Role for Sclerostin.

Fairfield H, Rosen CJ, Reagan MR.

Curr Mol Biol Rep. 2017 Jun;3(2):114-121. doi: 10.1007/s40610-017-0057-7. Epub 2017 Apr 18.

19.

Blocking FSH induces thermogenic adipose tissue and reduces body fat.

Liu P, Ji Y, Yuen T, Rendina-Ruedy E, DeMambro VE, Dhawan S, Abu-Amer W, Izadmehr S, Zhou B, Shin AC, Latif R, Thangeswaran P, Gupta A, Li J, Shnayder V, Robinson ST, Yu YE, Zhang X, Yang F, Lu P, Zhou Y, Zhu LL, Oberlin DJ, Davies TF, Reagan MR, Brown A, Kumar TR, Epstein S, Iqbal J, Avadhani NG, New MI, Molina H, van Klinken JB, Guo EX, Buettner C, Haider S, Bian Z, Sun L, Rosen CJ, Zaidi M.

Nature. 2017 Jun 1;546(7656):107-112. doi: 10.1038/nature22342. Epub 2017 May 24.

20.

Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma.

McDonald MM, Reagan MR, Youlten SE, Mohanty ST, Seckinger A, Terry RL, Pettitt JA, Simic MK, Cheng TL, Morse A, Le LMT, Abi-Hanna D, Kramer I, Falank C, Fairfield H, Ghobrial IM, Baldock PA, Little DG, Kneissel M, Vanderkerken K, Bassett JHD, Williams GR, Oyajobi BO, Hose D, Phan TG, Croucher PI.

Blood. 2017 Jun 29;129(26):3452-3464. doi: 10.1182/blood-2017-03-773341. Epub 2017 May 17.

21.

The skeletal cell-derived molecule sclerostin drives bone marrow adipogenesis.

Fairfield H, Falank C, Harris E, Demambro V, McDonald M, Pettitt JA, Mohanty ST, Croucher P, Kramer I, Kneissel M, Rosen CJ, Reagan MR.

J Cell Physiol. 2018 Feb;233(2):1156-1167. doi: 10.1002/jcp.25976. Epub 2017 Jun 6.

22.

MicroRNA Transfer Between Bone Marrow Adipose and Multiple Myeloma Cells.

Soley L, Falank C, Reagan MR.

Curr Osteoporos Rep. 2017 Jun;15(3):162-170. doi: 10.1007/s11914-017-0360-5. Review.

23.

Proteomic characterization of human multiple myeloma bone marrow extracellular matrix.

Glavey SV, Naba A, Manier S, Clauser K, Tahri S, Park J, Reagan MR, Moschetta M, Mishima Y, Gambella M, Rocci A, Sacco A, O'Dwyer ME, Asara JM, Palumbo A, Roccaro AM, Hynes RO, Ghobrial IM.

Leukemia. 2017 Nov;31(11):2426-2434. doi: 10.1038/leu.2017.102. Epub 2017 Mar 27.

PMID:
28344315
24.

A perspective on malignancy in the marrow.

Reagan MR, Lian JB, Rosen CJ, Stein GS.

J Cell Physiol. 2017 Dec;232(12):3218-3220. doi: 10.1002/jcp.25860. Epub 2017 May 16. Review.

25.

Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1.

Bar-Natan M, Stroopinsky D, Luptakova K, Coll MD, Apel A, Rajabi H, Pyzer AR, Palmer K, Reagan MR, Nahas MR, Karp Leaf R, Jain S, Arnason J, Ghobrial IM, Anderson KC, Kufe D, Rosenblatt J, Avigan D.

Br J Haematol. 2017 Mar;176(6):929-938. doi: 10.1111/bjh.14493. Epub 2017 Jan 20.

26.

Tissue-engineered 3D cancer-in-bone modeling: silk and PUR protocols.

Dadwal U, Falank C, Fairfield H, Linehan S, Rosen CJ, Kaplan DL, Sterling J, Reagan MR.

Bonekey Rep. 2016 Oct 19;5:842. eCollection 2016.

27.

The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma.

Manier S, Powers JT, Sacco A, Glavey SV, Huynh D, Reagan MR, Salem KZ, Moschetta M, Shi J, Mishima Y, Roche-Lestienne C, Leleu X, Roccaro AM, Daley GQ, Ghobrial IM.

Leukemia. 2017 Apr;31(4):853-860. doi: 10.1038/leu.2016.296. Epub 2016 Oct 24.

28.

Signaling Interplay between Bone Marrow Adipose Tissue and Multiple Myeloma cells.

Falank C, Fairfield H, Reagan MR.

Front Endocrinol (Lausanne). 2016 Jun 17;7:67. doi: 10.3389/fendo.2016.00067. eCollection 2016. Review.

29.

Abdominal adipose tissue in MGUS and multiple myeloma.

Veld J, O'Donnell EK, Reagan MR, Yee AJ, Torriani M, Rosen CJ, Bredella MA.

Skeletal Radiol. 2016 Sep;45(9):1277-83. doi: 10.1007/s00256-016-2425-4. Epub 2016 Jun 25.

PMID:
27344672
30.

Adipose, Bone, and Myeloma: Contributions from the Microenvironment.

McDonald MM, Fairfield H, Falank C, Reagan MR.

Calcif Tissue Int. 2017 May;100(5):433-448. doi: 10.1007/s00223-016-0162-2. Epub 2016 Jun 24. Review.

31.

The Use of Silk as a Scaffold for Mature, Sustainable Unilocular Adipose 3D Tissue Engineered Systems.

Abbott RD, Wang RY, Reagan MR, Chen Y, Borowsky FE, Zieba A, Marra KG, Rubin JP, Ghobrial IM, Kaplan DL.

Adv Healthc Mater. 2016 Jul;5(13):1667-77. doi: 10.1002/adhm.201600211. Epub 2016 May 19.

32.

Multiple myeloma in the marrow: pathogenesis and treatments.

Fairfield H, Falank C, Avery L, Reagan MR.

Ann N Y Acad Sci. 2016 Jan;1364:32-51. doi: 10.1111/nyas.13038. Review.

33.

Targeting vasculogenesis to prevent progression in multiple myeloma.

Moschetta M, Mishima Y, Kawano Y, Manier S, Paiva B, Palomera L, Aljawai Y, Calcinotto A, Unitt C, Sahin I, Sacco A, Glavey S, Shi J, Reagan MR, Prosper F, Bellone M, Chesi M, Bergsagel LP, Vacca A, Roccaro AM, Ghobrial IM.

Leukemia. 2016 May;30(5):1103-15. doi: 10.1038/leu.2016.3. Epub 2016 Feb 3.

PMID:
26859080
34.

Navigating the bone marrow niche: translational insights and cancer-driven dysfunction.

Reagan MR, Rosen CJ.

Nat Rev Rheumatol. 2016 Mar;12(3):154-68. doi: 10.1038/nrrheum.2015.160. Epub 2015 Nov 26. Review.

35.

CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation.

Roccaro AM, Mishima Y, Sacco A, Moschetta M, Tai YT, Shi J, Zhang Y, Reagan MR, Huynh D, Kawano Y, Sahin I, Chiarini M, Manier S, Cea M, Aljawai Y, Glavey S, Morgan E, Pan C, Michor F, Cardarelli P, Kuhne M, Ghobrial IM.

Cell Rep. 2015 Jul 28;12(4):622-35. doi: 10.1016/j.celrep.2015.06.059. Epub 2015 Jul 16.

36.

Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast.

Reagan MR, Liaw L, Rosen CJ, Ghobrial IM.

Bone. 2015 Jun;75:161-9. doi: 10.1016/j.bone.2015.02.021. Epub 2015 Feb 26. Review.

37.

The cancer glycome: carbohydrates as mediators of metastasis.

Glavey SV, Huynh D, Reagan MR, Manier S, Moschetta M, Kawano Y, Roccaro AM, Ghobrial IM, Joshi L, O'Dwyer ME.

Blood Rev. 2015 Jul;29(4):269-79. doi: 10.1016/j.blre.2015.01.003. Epub 2015 Jan 23. Review.

PMID:
25636501
38.

SDF-1 inhibition targets the bone marrow niche for cancer therapy.

Roccaro AM, Sacco A, Purschke WG, Moschetta M, Buchner K, Maasch C, Zboralski D, Zöllner S, Vonhoff S, Mishima Y, Maiso P, Reagan MR, Lonardi S, Ungari M, Facchetti F, Eulberg D, Kruschinski A, Vater A, Rossi G, Klussmann S, Ghobrial IM.

Cell Rep. 2014 Oct 9;9(1):118-128. doi: 10.1016/j.celrep.2014.08.042. Epub 2014 Sep 25.

39.

Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model.

Reagan MR, Mishima Y, Glavey SV, Zhang Y, Manier S, Lu ZN, Memarzadeh M, Zhang Y, Sacco A, Aljawai Y, Shi J, Tai YT, Ready JE, Kaplan DL, Roccaro AM, Ghobrial IM.

Blood. 2014 Nov 20;124(22):3250-9. doi: 10.1182/blood-2014-02-558007. Epub 2014 Sep 9.

40.

The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma.

Glavey SV, Manier S, Natoni A, Sacco A, Moschetta M, Reagan MR, Murillo LS, Sahin I, Wu P, Mishima Y, Zhang Y, Zhang W, Zhang Y, Morgan G, Joshi L, Roccaro AM, Ghobrial IM, O'Dwyer ME.

Blood. 2014 Sep 11;124(11):1765-76. doi: 10.1182/blood-2014-03-560862. Epub 2014 Jul 24.

41.

Engineered nanomedicine for myeloma and bone microenvironment targeting.

Swami A, Reagan MR, Basto P, Mishima Y, Kamaly N, Glavey S, Zhang S, Moschetta M, Seevaratnam D, Zhang Y, Liu J, Memarzadeh M, Wu J, Manier S, Shi J, Bertrand N, Lu ZN, Nagano K, Baron R, Sacco A, Roccaro AM, Farokhzad OC, Ghobrial IM.

Proc Natl Acad Sci U S A. 2014 Jul 15;111(28):10287-92. doi: 10.1073/pnas.1401337111. Epub 2014 Jun 30.

42.

Stem Cell Implants for Cancer Therapy: TRAIL-Expressing Mesenchymal Stem Cells Target Cancer Cells In Situ.

Reagan MR, Seib FP, McMillin DW, Sage EK, Mitsiades CS, Janes SM, Ghobrial IM, Kaplan DL.

J Breast Cancer. 2012 Sep;15(3):273-82. doi: 10.4048/jbc.2012.15.3.273. Epub 2012 Sep 28.

43.

Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects.

Reagan MR, Ghobrial IM.

Clin Cancer Res. 2012 Jan 15;18(2):342-9. doi: 10.1158/1078-0432.CCR-11-2212. Epub 2011 Nov 7. Review.

44.

Spider silk-based gene carriers for tumor cell-specific delivery.

Numata K, Reagan MR, Goldstein RH, Rosenblatt M, Kaplan DL.

Bioconjug Chem. 2011 Aug 17;22(8):1605-10. doi: 10.1021/bc200170u. Epub 2011 Jul 12.

45.

Concise review: Mesenchymal stem cell tumor-homing: detection methods in disease model systems.

Reagan MR, Kaplan DL.

Stem Cells. 2011 Jun;29(6):920-7. doi: 10.1002/stem.645. Review.

46.

Human bone marrow-derived MSCs can home to orthotopic breast cancer tumors and promote bone metastasis.

Goldstein RH, Reagan MR, Anderson K, Kaplan DL, Rosenblatt M.

Cancer Res. 2010 Dec 15;70(24):10044-50. doi: 10.1158/0008-5472.CAN-10-1254.

47.

Synthetic adipose tissue models for studying mammary gland development and breast tissue engineering.

Wang X, Reagan MR, Kaplan DL.

J Mammary Gland Biol Neoplasia. 2010 Sep;15(3):365-76. doi: 10.1007/s10911-010-9192-y. Epub 2010 Sep 12. Review.

PMID:
20835885
48.

Role of Cartilage Forming Cells in Regenerative Medicine for Cartilage Repair.

Sun L, Reagan MR, Kaplan DL.

Orthop Res Rev. 2010 Sep 1;2010(2):85-94.

49.

Electrospun silk biomaterial scaffolds for regenerative medicine.

Zhang X, Reagan MR, Kaplan DL.

Adv Drug Deliv Rev. 2009 Oct 5;61(12):988-1006. doi: 10.1016/j.addr.2009.07.005. Epub 2009 Jul 28. Review.

Supplemental Content

Loading ...
Support Center